SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS

C. Valdazo Martín1, J.J. García Albás1, M.Á. Andrés Moralejo1, H. Ayerra Pérez2, M. Rosado Ancín1, A. Santaolalla Sánchez1, N. Ramon Rigau1, A. Larrabeiti Echevarría3, C. Martínez Martínez1.

1Hospital Universitario Araba, Hospital Pharmacy, Vitoria-Gasteiz, Spain. 2Hospital Universitario Araba, Urology, Vitoria-Gasteiz, Spain.

Background and importance
Abiraterone is used in combination with prednisone, has liver metabolism and is an enzyme inhibitor. Enzalutamide has liver metabolism and is a potent enzyme inducer. Both are used to treat castrate metastatic prostate cancer (CMPC).

Aim and objectives
To analyze the switching between two antiandrogenic drugs, abiraterone and enzalutamide, in patients with CMPC.

Material and methods
Observational, retrospective, descriptive and unicentric study. It includes 127 patients with CMPC who began treatment with abiraterone or enzalutamide from January 2015 to March 2019. Clinical data from an outpatient pharmacy database and from medical history was analyzed. The reasons to switch were classified as safety, pharmacological interactions and galenic advantages.

Results

4 of the 50 patients who started with abiraterone switched to enzalutamide (8%), due to safety reasons in all cases because of side effects. The uncontrolled diabetes probably due to prednisone.

10 of the 77 patients who started treatment with enzalutamide switched to abiraterone (13%) due to safety reasons in 6 patients because of side effects. In 3 patients switching was due to drug interactions, which modified the efficacy and safety of enzalutamide and the other drug involved. 4 drugs were involved, 2 were antihypertensives (manidipine and verapamil) and 2 anticoagulants (rivaroxaban and acenocoumarol). In 1 patient switching was due to the galenic advantage of the smaller number and size of abiraterone tablets compared to enzalutamide capsules, due to the difficulty in swallowing due to an esophageal neoplasm.

Conclusion and relevance
Switching between abiraterone and enzalutamide in our patients was mostly due to safety reasons. Some side effects of the treatment with abiraterone and prednisone may have a steroidal origin. Enzalutamide is involved in pharmacokinetic and pharmacodynamic interactions with clinical relevance, so this is an important reason to switch. The smaller number and size of tablets could be a galenic advantage.